Pil Højgaard1,2, Christine Ballegaard1,2, René Cordtz1,2, Kristian Zobbe1,2, Marianne Clausen1, Bente Glintborg1,3, Lars Erik Kristensen2, Lene Dreyer1,2,4. 1. Rigshospitalet Gentofte, Center for Rheumatology and Spine Diseases, Aalborg University Hospital, Denmark. 2. Frederiksberg and Bispebjerg Hospitals, The Parker Institute, Aalborg University Hospital, Denmark. 3. Rigshospitalet Glostrup, The DANBIO registry, Copenhagen Center for Arthritis Research, Aalborg University Hospital, Denmark. 4. Department of Rheumatology, Aalborg University Hospital, Denmark.
Abstract
Objective: We aimed to investigate gender differences in disease manifestations, patient-reported outcomes, comorbidities and treatment effectiveness among patients with PsA treated with their first TNFα inhibitor (TNFI). Methods: In this observational cohort study, the DANBIO register provided prospectively collected data on PsA patients who initiated their first TNFI in 2000-15. Comorbidity information was achieved from the Danish Nationwide Patient Register. Response to treatment was assessed according to EULAR and ACR criteria at 3 and 6 months. Cox and logistic regression models analysed the impact of gender on TNFI persistence and response, respectively, while adjusting for a priori selected confounders including clinical-, laboratory- and patient-reported factors, comorbidities and lifestyle characteristics. Results: A total of 1750 PsA patients (935 women) were included. At baseline, women were older (49 years/47 years), more often smokers (32%/26%), had worse patient-reported scores (e.g. global score 71 mm/65 mm) and higher frequencies of hospital-diagnosed anxiety or depression (7%/4%) and chronic pulmonary disease (7%/3%) than men (all P < 0.01). Median TNFI persistence was 3.8 years (95% CI: 3.0, 5.7) in men vs 1.4 (1.1, 1.8) in women (P < 0.001). Men had higher odds of achieving response after 3 and 6 months, for example, adjusted odds ratio = 3.2 (1.6, 6.1) for EULAR good/moderate response (vs women) at 6 months. Conclusion: Male gender was strongly associated with greater TNFI treatment effectiveness. Adjustment for baseline risk factors including patient-reported outcomes, disease activity, comorbidities and lifestyle factors did not influence this relationship, which suggests a role of biological factors.
Objective: We aimed to investigate gender differences in disease manifestations, patient-reported outcomes, comorbidities and treatment effectiveness among patients with PsA treated with their first TNFα inhibitor (TNFI). Methods: In this observational cohort study, the DANBIO register provided prospectively collected data on PsA patients who initiated their first TNFI in 2000-15. Comorbidity information was achieved from the Danish Nationwide Patient Register. Response to treatment was assessed according to EULAR and ACR criteria at 3 and 6 months. Cox and logistic regression models analysed the impact of gender on TNFI persistence and response, respectively, while adjusting for a priori selected confounders including clinical-, laboratory- and patient-reported factors, comorbidities and lifestyle characteristics. Results: A total of 1750 PsA patients (935 women) were included. At baseline, women were older (49 years/47 years), more often smokers (32%/26%), had worse patient-reported scores (e.g. global score 71 mm/65 mm) and higher frequencies of hospital-diagnosed anxiety or depression (7%/4%) and chronic pulmonary disease (7%/3%) than men (all P < 0.01). Median TNFI persistence was 3.8 years (95% CI: 3.0, 5.7) in men vs 1.4 (1.1, 1.8) in women (P < 0.001). Men had higher odds of achieving response after 3 and 6 months, for example, adjusted odds ratio = 3.2 (1.6, 6.1) for EULAR good/moderate response (vs women) at 6 months. Conclusion: Male gender was strongly associated with greater TNFI treatment effectiveness. Adjustment for baseline risk factors including patient-reported outcomes, disease activity, comorbidities and lifestyle factors did not influence this relationship, which suggests a role of biological factors.
Authors: Philip J Mease; Neil A Accortt; Sabrina Rebello; Carol J Etzel; Ryan W Harrison; Girish A Aras; Mahdi M F Gharaibeh; Jeffrey D Greenberg; David H Collier Journal: Rheumatol Int Date: 2019-07-18 Impact factor: 2.631
Authors: Marc Fenster; Quazim A Alayo; Aava Khatiwada; Wenfei Wang; Christina Dimopoulos; Alexandra Gutierrez; Matthew A Ciorba; George P Christophi; Robert P Hirten; Christina Ha; Poonam Beniwal-Patel; Benjamin L Cohen; Gaurav Syal; Andres Yarur; Anish Patel; Jean-Frederic Colombel; Joel Pekow; Ryan C Ungaro; David T Rubin; Parakkal Deepak Journal: Clin Gastroenterol Hepatol Date: 2020-10-14 Impact factor: 13.576
Authors: Sandy R McBride; Maria C Fargnoli; Anne-Claire Fougerousse; Marta García Bustínduy; Louise Catton; Lerzan Senturk; Cécile Ecoffet; Jan Koren; Laura Andreoli; Laura C Coates; Alice Titialii Journal: Int J Womens Dermatol Date: 2021-08-28
Authors: A Prior-Español; C Sánchez-Piedra; J Campos; F J Manero; C Pérez-García; C Bohórquez; N Busquets-Pérez; J M Blanco-Madrigal; C Díaz-Torne; F Sánchez-Alonso; L Mateo; S Holgado-Pérez Journal: Sci Rep Date: 2021-05-27 Impact factor: 4.379